11/15/2026
Results of a randomized double-blind trial in patients with suboptimally controlled hyperlipidemia, published recently in :
➡️ Quarterly SHR-1918 (an ANGPTL3 antibody) significantly ⬇️ LDL-C (~21–25%) and triglycerides (~50–59%) at 24 weeks.
Get the full details: https://bit.ly/48nLPxo